Cargando…

Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial

GSK961081 (batefenterol) is a novel bifunctional molecule composed of a muscarinic antagonist and a β(2)‐agonist. The aims of this substudy were (1) to characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of GSK961081 in patients with moderate-to-severe chronic obstructive pul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambery, Claire L., Wielders, Pascal, Ludwig-Sengpiel, Andrea, Chan, Robert, Riley, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561049/ https://www.ncbi.nlm.nih.gov/pubmed/26286203 http://dx.doi.org/10.1007/s40268-015-0104-x

Ejemplares similares

A new class of bronchodilator improves lung function in COPD: a trial with GSK961081
por: Wielders, Pascal L.M.L., et al.
Publicado: (2013)

Use of Propranolol Blockade to Explore the Pharmacology of GSK961081, a Bi-Functional Bronchodilator, in Healthy Volunteers: Results from Two Randomized Trials
por: Norris, Virginia, et al.
Publicado: (2014)

Pharmacokinetics, Excretion, and Mass Balance of [(14)C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
por: Ambery, Claire, et al.
Publicado: (2018)

Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently
por: Ambery, Claire, et al.
Publicado: (2018)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
por: Crim, Courtney, et al.
Publicado: (2019)

Multitargeting nature of muscarinic orthosteric agonists and antagonists
por: Myslivecek, Jaromir
Publicado: (2022)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020)

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013)

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015)

Muscarinic Receptors and Their Antagonists in COPD: Anti-Inflammatory and Antiremodeling Effects
por: Karakiulakis, George, et al.
Publicado: (2012)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M(1)‐acetylcholine receptor agonist: A randomized cross‐over trial
por: Bakker, Charlotte, et al.
Publicado: (2021)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy
por: Martin, Mickaël, et al.
Publicado: (2017)

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
por: Ismaila, Afisi Segun, et al.
Publicado: (2015)

Muscarinic receptor signaling in the pathophysiology of asthma and COPD
por: Gosens, Reinoud, et al.
Publicado: (2006)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy
por: Marshall, Helen, et al.
Publicado: (2023)

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients
por: Milara, Javier, et al.
Publicado: (2019)

Effects of (a Combination of) the Beta(2)-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction
por: Maarsingh, Harm, et al.
Publicado: (2021)

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT(3) receptors
por: Lochner, Martin, et al.
Publicado: (2016)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo
por: Thompson, Karen J., et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study
por: Cahn, Anthony, et al.
Publicado: (2013)

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β(2) Adrenergic Receptor Agonist Navafenterol in Human Small Airways
por: Jude, Joseph Antony, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey
por: Racz, Boglarka, et al.
Publicado: (2020)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy
por: Jakubík, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_293skcmetc6rmst54kv1ndjfqb